CCS

Looking forward to attending ISPOR—The Professional Society for Health Economics and Outcomes Research 2026 in Philadelphia next week. CCS will be sharing findings from our randomized study evaluating how structured coaching and education at the time of CGM initiation impacts glycemic and patient-reported outcomes. One of the recurring themes in diabetes care is that CGM access alone is not enough. How individuals are supported in the first weeks and months after therapy initiation matters. If you’ll be at ISPOR, I’d love to connect and invite you to stop by our poster. Jason Allaire

CMS is continuing to modernize the prior authorization process for DMEPOS suppliers — and that could be a big win for both patients and providers. 👏 Recent CMS updates are designed to streamline prior authorizations, reduce administrative burden, and reward suppliers with strong compliance records through a potential “gold carding” exemption process. Suppliers with high provisional affirmation rates may eventually qualify for fewer prior authorization requirements. Here are important dates to take note of: June 1, 2026 — First annual “gold carding” exemption cycle officially begins for qualifying DME suppliers. January 1, 2027 — CMS electronic prior authorization API requirements go live for impacted payers. This is the major interoperability milestone many providers and suppliers are preparing for now. October 1, 2027 — Proposed compliance date for expanded electronic prior authorization rules, including drug-related prior authorization workflows and new decision timelines. This is where experienced DME partners can truly make a difference. Companies like CCS Medical have built entire teams around navigating insurance requirements, documentation workflows, and patient support for diabetes care. As CMS continues evolving these programs, suppliers that invest in compliance, education, and proactive communication will be positioned to better serve both providers and patients. The healthcare industry talks a lot about “patient-centered care” — but simplifying access to medically necessary supplies is one of the most impactful ways to deliver it. The future of DME isn’t just about shipping supplies. It’s about: 📈 Operational excellence 🤝 Provider collaboration 📚 Patient education ⚡ Speed to therapy And ultimately, helping people manage chronic conditions with fewer barriers. Excited to see CMS taking steps toward a smarter and more efficient authorization process for the DME industry. #DME #DiabetesCare #CGM #Medicare #PriorAuthorization #HealthcareInnovation #CCSMedical #ChronicCare #MedicalSupplies #HealthcareLeadership

Cardiovascular disease remains one of the leading causes of complications and death for people living with diabetes. Appreciate the American Heart Association continuing to elevate the importance of cardiometabolic care through initiatives like Outpace CVD. #LivingConnected was designed to support cardiometabolic health through blood pressure support, weight management, lifestyle coaching, medication adherence, and ongoing education alongside CGM therapy. I especially appreciate the focus on helping organizations evaluate their current approach to diabetes care and identify potential gaps in support, education, and follow-up over time. #DiabetesCare #CardiovascularDisease #ASCVD #PopulationHealth

Loneliness. The feeling that you’re navigating life on your own. It’s more common than we think. According to the CDC, about 1 in 3 adults report feeling lonely, and for many, it sits quietly in the background of daily life. Loneliness doesn’t always look like isolation. Sometimes it shows up in quieter ways, like not asking questions, starting something but not staying with it, or gradually falling off track. We often label this “non-adherence,” “non-compliance,” or “disengagement,” but it’s often something else. We spend a lot of time focusing on access. The right medication. The right technology. The right care plan. But access alone doesn’t change outcomes. If we want to see something different, we have to get closer to the lived experience. Not just what someone has access to, but whether they feel supported and connected enough to keep going. When someone feels like they’re navigating life on their own, it’s not surprising when the outcome reflects that. Connection isn’t a "nice to have" in care. It’s part of the intervention.

I have spent much of my career in cardiometabolic care. And I keep coming back to the same question: Why are we still intervening so late? The data reflects what we see every day. Access to DSMES is inconsistent. Support isn’t always there when it’s needed. Benefits tend to activate after things have already started to slip. After years of progress, complications are rising again. Because by the time we measure the outcome, we are often measuring the result of a system that engaged too late. This isn’t just about individual behavior. It’s about when care shows up. We have the knowledge. We have the tools. What’s missing is consistency. We know what works. The question is whether we show up in time. Curious how others are thinking about shifting engagement earlier in the journey.

Excited to be at the Cleveland Breakthrough T1D Community Summit today representing Beta Bionics and the iLet Bionic Pancreas! Stop by and say hi, ask questions, and learn more about how we’re helping people with diabetes see incredible outcomes with less daily burden. We’re bringing a new, different approach that can help make life feel easier. Looking forward to meeting everyone and being part of such an amazing community today! https://lnkd.in/gD7nWxQe